ICD10 code of 19q13.11 Microdeletion Syndrome and ICD9 code

19q13.11 Microdeletion Syndrome does not have a unique, disease-specific ICD-10 or ICD-9 code, as it is a rare chromosomal anomaly classified under broader categories for chromosomal deletions. Clinicians typically use ICD-10 code Q93.5 (Other deletions of part of a chromosome) or Q93.8 (Other chromosomal abnormalities) to document the diagnosis for billing and medical record purposes.

Why is there no specific ICD code for 19q13.11 Microdeletion Syndrome?

Because 19q13.11 Microdeletion Syndrome is a rare genetic condition, it is categorized within the international coding systems under general chromosomal disorders. These systems, such as ICD-10, are designed to cover thousands of conditions, and rare microdeletions are often grouped together. For medical documentation, your physician will likely use a combination of the specific cytogenetic finding (the deletion) and the clinical features (such as developmental delay) to ensure accurate coding for insurance and research tracking.

What are the core clinical features of 19q13.11 Microdeletion Syndrome?

19q13.11 Microdeletion Syndrome is characterized by a loss of genetic material on the long arm of chromosome 19. Clinical manifestations can vary significantly between individuals, but common findings documented by researchers and the 19 members of our DiseaseMaps community include:

• Developmental delays, particularly in speech and motor milestones.


• Distinctive facial features, often including a prominent forehead or specific ear morphology.


• Feeding difficulties and failure to thrive in early infancy.


• Structural anomalies, such as hypospadias in males or skeletal variations.


• Mild to moderate intellectual disability.

How is 19q13.11 Microdeletion Syndrome diagnosed?

The definitive diagnosis of 19q13.11 Microdeletion Syndrome is achieved through chromosomal microarray analysis (CMA). This high-resolution testing detects the exact start and end points of the deletion. Genetic counselors often review these results to determine if the deletion is *de novo* (occurring spontaneously) or inherited from a parent, which is vital for family planning and recurrence risk assessment.

Next steps

• Consult with a clinical geneticist to interpret microarray results and discuss familial implications.


• Connect with the 19 individuals on DiseaseMaps.org who share this diagnosis to exchange practical insights.


• Coordinate care through a multidisciplinary team, including speech therapists and pediatric specialists.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Information on chromosomal microdeletion syndromes.


• Orphanet: Database for rare diseases and orphan drugs (ORPHA:314562).


• OMIM (Online Mendelian Inheritance in Man): Clinical synopsis for 19q13.11 deletions.


• PubMed: Peer-reviewed clinical literature on the phenotypic spectrum of 19q13.11 Microdeletion Syndrome.